Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib

BACKGROUND: This multicentre phase II trial (DOVIGIST) evaluated the antitumour activity of dovitinib as second-line treatment of patients with gastrointestinal stromal tumour (GIST) refractory to imatinib or who do not tolerate imatinib. METHODS: Patients received oral dovitinib 500 mg day(−1), 5 d...

Descripción completa

Detalles Bibliográficos
Autores principales: Joensuu, Heikki, Blay, Jean-Yves, Comandone, Alessandro, Martin-Broto, Javier, Fumagalli, Elena, Grignani, Giovanni, Del Muro, Xavier Garcia, Adenis, Antoine, Valverde, Claudia, Pousa, Antonio Lopez, Bouché, Olivier, Italiano, Antoine, Bauer, Sebastian, Barone, Carlo, Weiss, Claudia, Crippa, Stefania, Camozzi, Maura, Castellana, Ramon, Le Cesne, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672922/
https://www.ncbi.nlm.nih.gov/pubmed/28850565
http://dx.doi.org/10.1038/bjc.2017.290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672922/
https://www.ncbi.nlm.nih.gov/pubmed/28850565
http://dx.doi.org/10.1038/bjc.2017.290

Ejemplares similares